Abstract
Since its identification, the novel coronavirus “severe acute respiratory syndrome coronavirus 2 “(SARS-CoV-2) In in late 2019 AT Wuhan, China, by the World Health Organization (WHO), which cause the coronavirus disease 2019, is rapidly spreading, resulting in the global pandemic. As of 19 December 2022, more than 64 million confirmed cases and 6,645,812 deaths have been reported across the world. Over time, the SARS-CoV-2 acquired genetic mutations resulting in multiple types of SARS-CoV-2 variants and subvariants that have been confirmed. The Omicron (B.1.1.529) variant was identified later in November 2021, with enhanced immune escape and was followed with various sublineages due to mutations in the spike protein of the SARS-CoV-2. However, rapid resurge in COVID-19 reports by Omicron subvariant BF.7(BA.2.75.2) in China and other countries, alarming global threat. The present systematic review was conducted using the MeSH terms and keywords “Omicron” AND “BA.5.2.1.7” OR “BF.7” in Pub Med, Google Scholar and MedRXiv database and grey literature from the authentic database and websites. We identified a total of 14 eligible studies. We have reviewed all the eligible available studies to understand the viral mutations, and factors associated with the increase in the reports of COVID-19 cases in China and across the world and to evaluate the effectiveness of vaccination and monoclonal antibodies against the BF.7 variant.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
none to declare
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: csanten7{at}gmail.com, Email: krishnachaitanya.amerneni{at}med.wmich.edu, Email: mohanakrishna.ghanta{at}gmail.com, Email: pad.mythili{at}gmail.com, email: madhubhargavi196{at}gmail.com, email: madhu.adusumilli3{at}gmail.com, Email: sophia.dr{at}gmail.com, Email: madhavrao.pharm{at}aiimsmangalagiri.edu.in, Email: neolog.raj{at}gmail.com, Email: bhawnaajmer001{at}gmail.com
Prior publication: Nil
Sources of Support: Nil
Conflicts of interest: Nil
Read and approved by all authors: Yes.
Author names corrected and corrected grammatical mistakes.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
